Trials / Recruiting
RecruitingNCT05307731
Fingolimod for Type 2 Diabetes Mellitus
Fingolimod for Type 2 Diabetes Mellitus: a Pilot, Prospective, Randomized, and Open Label Single-center Study
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- General Hospital of Shenyang Military Region · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fingolimod | 0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM |
| DRUG | guideline-based treatment for DM | guideline-based treatment for DM |
Timeline
- Start date
- 2022-03-15
- Primary completion
- 2026-03-15
- Completion
- 2026-03-15
- First posted
- 2022-04-01
- Last updated
- 2025-08-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05307731. Inclusion in this directory is not an endorsement.